Purolite and Repligen to commercially launch novel CH1 affinity resin

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Purolite Resin bioprocessing Bispecific antibodies Manufacturing Biologics

Ion exchange resin manufacturer Purolite and bioprocessing technology firm Repligen have announced the commercial launch of Praesto CH1, an affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.

This latest product, which was developed for commercialization by Purolite as part of a multi-year partnership with Repligen, combines Purolite’s patented Jetted beads manufacturing process with Repligen’s ligand technology.

According to both companies, the affinity resign aims to address previously unmet challenges in specialized mAb purification.

Purolite vice president of research and development, Jennifer Sorrells, said: “The launch of Praesto CH1 represents the latest offering in Purolite’s growing innovation toolbox for the purification of biologics.

“Our strategic partnership with Repligen brings leading technologies together to unlock new purification strategies that address our customers’ increasingly diverse biotherapeutic molecules, and the unique purification challenges that these can present."

The new CH1 purification resin builds on Purolite’s​ current protein A resin portfolio, demonstrating high selectivity for antibodies and related fragments containing the human CH1 domain.

This allows for the capture of bispecific antibodies and antibody fragments, as well as the removal of mis-paired species, providing an alternative for the purification of antibody variants when Protein A resins are not suitable.

Ralf Kuriyel, senior vice president of research and development at Repligen, commented: “It’s fantastic to see the Praesto CH1 resin come to market through our partnership with the Purolite team. We continue to make real advances in our Proteins franchise, supporting the success of the Praesto family of resins as Purolite’s exclusive development and manufacturing scale-up partner.

“This cross-linked agarose-based resin was specifically and successfully engineered for high dynamic binding capacity to the CH1 region of antigen-binding fragments from human immunoglobins (IgGs) and monoclonal antibodies (mAbs), and we believe it is particularly well positioned for market success.”

The news comes after Purolite recently announced its investment in a new bioprocessing production facility based in Landenberg, Pennsylvania, the company’s fourth location in the state.

Related news

Show more

Follow us

Webinars

Headlines